Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis

This publication has 34 references indexed in Scilit:

• Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization
  Gene Therapy, 2003
• Periocular Gene Transfer ofsFlt-1Suppresses Ocular Neovascularization and Vascular Endothelial Growth Factor-Induced Breakdown of the Blood-Retinal Barrier
  Human Gene Therapy, 2003
• Inhibition of Retinal Neovascularization by Intraocular Viral-Mediated Delivery of Anti-angiogenic Agents
  Molecular Therapy, 2002
• Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration11InternetAdvance publication at ajo.com. May 7, 2002.
  American Journal of Ophthalmology, 2002
• Inhibition of Choroidal Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin
  The American Journal of Pathology, 2001
• Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy
  Experimental and Clinical Endocrinology & Diabetes, 2000
• Systemic Levels Contribute Significantly to Increased Intraocular IGF-I, IGF-II and IFG-BP3 in Proliferative Diabetic Retinopathy
  Hormone and Metabolic Research, 2000
• Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrombin
  Science, 1999
• Dramatic Inhibition of Retinal and Choroidal Neovascularization by Oral Administration of a Kinase Inhibitor
  The American Journal of Pathology, 1999
• Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.
  Journal of Clinical Investigation, 1993